Fisher & Paykel Healthcare Corporation Limited

As of March 31, 2026, Fisher & Paykel Healthcare Corporation Limited carries a market capitalization of 21.96B, placing it among publicly traded companies globally. Its enterprise value stands at 21.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fisher & Paykel Healthcare Corporation Limited's next confirmed earnings release is scheduled for November 26, 2026.

As of March 31, 2026, Fisher & Paykel Healthcare Corporation Limited has 587.28M shares outstanding.

As of March 31, 2026, Fisher & Paykel Healthcare Corporation Limited trades at a trailing price-to-earnings ratio of 46.84. The price-to-sales ratio is 9.51, and the price-to-book ratio stands at 10.38.

As of March 31, 2026, Fisher & Paykel Healthcare Corporation Limited trades at an EV/EBITDA multiple of 34.01 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 45.30 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 21.64B versus a market cap of 21.96B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Fisher & Paykel Healthcare Corporation Limited maintains a current ratio of 2.31, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.91, indicating elevated leverage, while an interest coverage ratio of 61.79 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Fisher & Paykel Healthcare Corporation Limited posted a return on equity (ROE) of 23.39, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.89 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.34, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 22.12, useful for judging operating efficiency across full business cycles. The company generates approximately 301,318.37 in revenue per employee across its workforce of 7,661.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.50 indicates how many times Fisher & Paykel Healthcare Corporation Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Fisher & Paykel Healthcare Corporation Limited recorded 163.00M in income tax expense. That works out to an effective tax rate of 25.81, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 631.50M, leaving 468.50M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Fisher & Paykel Healthcare Corporation Limited's stock has gained approximately 36.95% over the past 52 weeks. The 50-day moving average sits at 45.47, while the 200-day moving average is 40.16.

Over the twelve months ended March 31, 2026, Fisher & Paykel Healthcare Corporation Limited generated 2.31B in revenue and converted that into 468.50M in net income, yielding earnings per share of 0.79. EBITDA reached 636.40M, while operating income came in at 477.80M.

As of March 31, 2026, Fisher & Paykel Healthcare Corporation Limited holds 461.10M in cash and equivalents against 146.10M in total debt, resulting in a net debt position of -401.30M. Total book value stands at 2.12B, with working capital of 654.40M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Fisher & Paykel Healthcare Corporation Limited posted a gross margin of 63.68, reflecting its pricing power and cost economics. The operating margin of 20.70 and net profit margin of 20.30 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Fisher & Paykel Healthcare Corporation Limited paid dividends of 0.43 per share. The dividend payout ratio of 53.85 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.26, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fisher & Paykel Healthcare Corporation Limited shareholders.

Fisher & Paykel Healthcare Corporation Limited's most recent stock split took place on October 4, 2004 with a 1:5 split ratio.

As of March 31, 2026, Fisher & Paykel Healthcare Corporation Limited has an Altman Z-Score of 20.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.